Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Asan Medical Center
With
Boryung Pharmaceutical Co., Ltd
Prospective, Open-label, Randomized phase II, single institution trial that compared chemotherapy guided by traditional evaluation based on RECIST versus chemotherapy guided by FDG-PET (metabolic) response.
3. No evidence of prior malignancies for 3 years except treated basal cell or squamous cell carcinoma of skin and carcinoma in situ of uterine cervix.
4. Measurable disease by RECIST criteria.
5. Adequate organ function as follows.
* Seum AST/ALT \< 2.5 x Upper normal limit (UNL) (if hepatic metastasis \< 5 x UNL)
* Total bilirubin \< 1.5 x UNL
* Serum creatinine \< 1.5 mg/dL
* Absolute neutrophil count \> 1500/uL
* Platelet \> 100,000/uL
* Hemoglobin \> 9.0 g/dL
6. ECOG Performance status 0-1 7 Age \> 18
8\. If previously treated with major surgery, it should be over at least 4 weeks. And if previously treated with radiotherapy, it should be over at least 2 weeks.
9\. Written consent
You may not be if
1. Previous chemotherapy.
2. Symptomatic brain metastasis.
3. Concurrent severe medical illness.
4. Pregnancy and lactation.
5. If there are findings which may increase risk with chemotherapy or inhibit to analyze the result of clinical trial.
